A phase I, single ascending dose trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of VTP 43742 in healthy volunteers

Trial Profile

A phase I, single ascending dose trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of VTP 43742 in healthy volunteers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 May 2016

At a glance

  • Drugs VTP 43742 (Primary)
  • Indications Autoimmune disorders; Multiple sclerosis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Vitae Pharmaceuticals
  • Most Recent Events

    • 17 May 2016 Results of this and other study (see profile 255432) presented at the IMMUNOLOGY 2016™ American Association of Immunologists Annual Meeting
    • 09 May 2016 Data will be presented at the IMMUNOLOGY 2016, the American Association of Immunologists' annual meeting according to a Vitae Pharmaceuticals media release.
    • 08 Sep 2015 Top-line results were published in a Vitae Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top